INHALE-1 is a 26-week, open-label clinical trial that randomized 230 subjects aged 4-17 years with type 1 or type 2 diabetes to either inhaled pre-meal insulin or multiple daily injections (MDI) of ...

MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children.

Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression The INHALE-1 study is a 26-week, ...

For adults with type 1 diabetes, a regimen of inhaled Technosphere insulin (TI) plus insulin degludec is noninferior t ...

MannKind Corporation announces six-month results from phase 3 INHALE-1 of Afrezza inhalation powder in children and adolescents: Danbury, Connecticut Wednesday, December 18, 2024, ...

MannKind Corporation (NASDAQ: MNKD) are trading lower Monday. The company released its six-month results from its Phase 3 ...

Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

MannKind Corporation is focused on inhaled therapies for endocrine and orphan lung diseases. Check out my recommendation for ...

(RTTNews) - MannKind Corporation (MNKD) Monday reported positive six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder, a rapid-acting inhaled human insulin, in individuals ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...